Group 1 - The 2025 Guangdong-Hong Kong-Macao Greater Bay Area Artificial Intelligence and Robotics Industry Conference was held from December 12 to 14, showcasing the latest achievements in the integration of AI and manufacturing [1] - The conference highlighted the construction achievements of the "National Artificial Intelligence Pilot Base," which is the only national-level pilot platform focusing on mobile terminals, co-built by Shenzhen and Dongguan, and constructed by China Unicom [1] - The base aims to enhance "terminal innovation" and "manufacturing efficiency" by establishing five foundational capabilities: computing power, data, models, applications, and security [1] Group 2 - Guangdong Unicom, in collaboration with various organizations, launched the "Guangdong Artificial Intelligence + Manufacturing Industry Alliance" to tackle common technical challenges and promote resource collaboration and achievement transformation [2] - The alliance includes partnerships with major companies such as Huawei, TCL, Midea, and others to accelerate the transformation of technological achievements into industrial practices [2] - Two platforms were officially launched: the "Yuanjing·Wanwuh Industrial Intelligence Platform" and the "Ge Wu·Embodied Intelligent Robot Collaborative Platform," aimed at empowering the entire production process with intelligent capabilities [1][2]

Group 1 - The 2025 China Innovation and Entrepreneurship Achievement Trading Conference and the China Overseas Talent Exchange Conference opened in Guangzhou, marking the first comprehensive market-oriented approach for both events [1] - The joint conference aims to accelerate the integration of talent, technology, and industry, serving as a significant practice for Guangzhou to support national strategies and align with innovation trends [1] Group 2 - The 2025 Guangzhou Unicorn Innovation Enterprise List was released, featuring 210 companies, including 26 "unicorn" companies, 105 "future unicorns," and 79 "seed unicorns" [2] - The number of "future unicorn" companies increased by 4% compared to last year, while "seed unicorn" companies grew by 13% [2] - High-tech enterprises make up 77% of the listed companies, with 63% concentrated in information technology, biomedicine, artificial intelligence, and advanced manufacturing [2] Group 3 - The list showcases a well-structured ecosystem with strong international competitiveness, as leading "unicorns" average 496 intellectual property rights and 107 invention patents [3] - Notable companies include GAC Aion, Yuanchip Semiconductor, and Zhongke Aerospace, all valued over 10 billion RMB, demonstrating large scale, mature business models, and high globalization [3] - "Future unicorns" exhibit robust technical capabilities, with an average of 125 intellectual property rights and 30 invention patents, focusing on niche areas such as targeted cancer drug development and AI robotics [3] Group 4 - "Seed unicorn" companies show strong innovation vitality, averaging 34 intellectual property rights, and include leaders in quantum technology and high-end semiconductor packaging [4] - The conference also launched the "Most Influential Emerging Overseas Returnee Entrepreneur" list and the Greater Bay Area Future Unicorn list [4] - The Guangzhou State-owned Assets and Enterprises Think Tank Alliance was established, and the finals of the 2025 Overseas Talent Entrepreneurship Competition were initiated [4] Group 5 - The conference has facilitated project conversion worth over 998 billion RMB in the past decade, aiming to bridge the gap in project implementation [5] - Innovative projects showcased include a multi-sensory system for tinnitus treatment and a preservation technology for lychee, indicating significant market potential [5] - The Guangdong Provincial Hospital of Traditional Chinese Medicine presented various health products developed by the hospital [5] Group 6 - The Overseas Talent Exchange Conference has attracted over 50,000 overseas talents, facilitating their return to domestic development [6] - An international talent recruitment fair was held, featuring numerous tech companies offering attractive positions, with a high percentage of candidates holding master's degrees or higher [6] - The recruitment fair provided a comprehensive service experience for job seekers, including resume diagnostics and career development guidance [6]

Core Viewpoint - The biopharmaceutical sector is expected to experience significant performance divergence among its sub-sectors before the third quarter of 2025, with industry revenue and profit growth rates initially declining before rebounding, as the pressures from high baselines, centralized procurement, and anti-corruption measures have been largely absorbed [1] Group 1: Innovative Drugs - The commercial insurance innovation drug catalog is set to debut in 2025, which is anticipated to drive incremental payments for innovative drug products [2] - The domestic new drug development is accelerating, with lower costs and favorable macro policies, leading to a global leadership position in innovative drug development, contributing approximately one-third of the global innovative R&D pipeline by 2025 [2] - The overseas rights BD transactions are driving the revaluation of innovative drug assets, with a continuous increase in the proportion of Chinese innovative drug license-outs [2] Group 2: CXO and Life Sciences - The CXO market is witnessing improved supply-demand dynamics, with CDMO companies entering a high prosperity cycle due to strong demand for new molecules like ADCs and peptides [2] - The life sciences upstream sector is experiencing a comprehensive recovery in downstream demand, with listed companies actively pursuing mergers and acquisitions to expand [3] Group 3: AI in Healthcare - The "Artificial Intelligence+" policy is leading to widespread applications of AI in healthcare, with significant developments driven by companies like Deepseek [3] Group 4: High-end Medical Equipment - The high-end medical equipment sector is poised for growth due to domestic procurement recovery, import substitution, and accelerated international expansion [3] Group 5: Orthopedic Joint Consumables - The negative impact of centralized procurement is clearing, and the aging population is driving market expansion, with potential growth in surgical robotics [3] Group 6: Traditional Chinese Medicine - There are signs of operational improvement in traditional Chinese medicine, with factors like flu season and basic drug catalog adjustments potentially catalyzing a new market cycle [4]

证券代码：600332 证券简称：白云山 公告编号：2025-086 一、《药品生产许可证》基本情况 企业名称：广州白云山星珠药业有限公司 许可证编号：粤20160117 分类码：Ay 注册地址：广州市从化明珠工业园创业大道南4号 广州白云山医药集团股份有限公司 关于子公司《药品生产许可证》注销的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 近日，广东省药品监督管理局发布了《广东省药品监督管理局关于注销〈药品生产许可证〉的通告 （2025年第102号）》，广州白云山医药集团股份有限公司（以下简称"本公司"）子公司广州白云山星 珠药业有限公司（以下简称"星珠药业"）《药品生产许可证》已注销，本次注销的原因是星珠药业进行 生产经营业务调整，在生产范围为中药饮片的《药品生产许可证》有效期届满后不再申请重新发证。现 将相关情况公告如下： 发证机关：广东省药品监督管理局 有效期至：2025年9月9日 生产地址和生产范围：广州市从化明珠工业园创业大道南4号， 特此公告。 广州白云山医药集团股份有限公司董事会 2025年12月15日 ...

Core Insights - The report highlights a significant shift in the pharmaceutical and biotechnology industry, moving from a follower to a leader in innovation, particularly in the context of international expansion and high-end product development [3][4] - The overall industry revenue and profit growth are expected to rebound after a period of decline, driven by the recovery of innovative drugs and the CXO sector [3][4] Industry Performance and Valuation Dynamics - In the first three quarters of 2025, the pharmaceutical sector experienced a notable divergence in performance across sub-sectors, with innovative drugs and CXO showing signs of recovery while others lagged [3][15] - The total revenue for 461 A-share listed companies in the pharmaceutical sector is projected to reach CNY 24,640 billion in 2024, with a slight decline of 0.7% year-on-year [15][18] - The overall valuation of the pharmaceutical sector remains low compared to historical averages, with innovative drugs benefiting from expectations of business development (BD) transactions [3][4][15] Innovative Drugs - The report emphasizes that the rapid development and lower costs of new drug development in China have positioned the country as a global leader, contributing approximately one-third of the global innovative R&D pipeline in 2025 [4][14] - The introduction of the commercial insurance innovative drug directory in 2025 is expected to stimulate payment growth for innovative drug products [3][4] CXO Sector - The CXO market is witnessing improved supply and demand dynamics, with CDMO companies entering a high-growth cycle due to strong demand for new molecular entities [4][15] - Key players in the CDMO space, such as WuXi AppTec, are highlighted for their robust project pipelines and market positioning [4][15] Life Sciences Upstream - The recovery in downstream demand is driving revenue growth in the life sciences sector, with companies actively pursuing mergers and acquisitions to expand their market presence [4][15] - Companies like Bide Pharmaceutical and Haoyuan Pharmaceutical are noted for their strong cash reserves and strategic acquisition activities [4][15] AI in Healthcare - The report discusses the impact of AI in healthcare, driven by government policies and the development of large-scale AI models, with companies like JD Health and Yimaitong being key players [4][5] High-End Medical Equipment - The high-end medical equipment sector is expected to benefit from a recovery in domestic procurement, import substitution, and accelerated international expansion [4][5] - Companies such as United Imaging and Kaili Medical are identified as potential beneficiaries of these trends [4][5] Orthopedic Consumables - The orthopedic market is expanding due to an aging population, with the negative impacts of centralized procurement clearing up, leading to a resurgence in demand for robotic-assisted surgeries [4][5] Traditional Chinese Medicine - Some traditional Chinese medicine companies are showing signs of revenue and profit improvement, driven by seasonal demand and adjustments in the essential medicine directory [4][5]

证券日报网讯 12月15日，白云山在互动平台回答投资者提问时表示，公司应收账款主要集中在医药流 通业务，公司通过优化客户信用管理、强化回款机制和资产证券化等工具控制风险及提升资金周转效 率。 （文章来源：证券日报） ...

证券日报网讯 12月15日晚间，白云山发布公告称，近日，广东省药品监督管理局发布了《广东省药品 监督管理局关于注销的通告（2025 年第 102 号）》，广州白云山医药集团股份有限公司（以下简称"本 公司"）子公司广州白云山星珠药业有限公司（以下简称"星珠药业"）《药品生产许可证》已注销，本 次注销的原因是星珠药业进行生产经营业务调整，在生产范围为中药饮片的《药品生产许可证》有效期 届满后不再申请重新发证。 （编辑 楚丽君） ...

Core Insights - The forum "Dialogue and Coexistence" organized by Phoenix TV Group successfully took place in Kuala Lumpur, Malaysia, focusing on the globalization paths of Chinese enterprises and the cooperation between China and Malaysia [1][4] - The event gathered over a hundred representatives from both countries, including government officials, business leaders, and cultural figures, to explore new opportunities for mutual growth [1] Group 1: Forum Overview - The forum was supported by Malaysia's Ministry of Entrepreneur Development and Cooperatives and the Ministry of Tourism, Arts and Culture [1] - Phoenix TV aims to promote Chinese culture and facilitate international exchanges, emphasizing its commitment to deepening engagement in Malaysia [3] Group 2: Keynote Speeches - Hextar Group's CEO shared insights on the company's transformation from traditional industries to a diversified conglomerate, highlighting successful collaborations with Chinese firms like Luckin Coffee [6] - Honor's South Pacific President discussed the brand's strategies for integrating into the Malaysian market and resonating with local youth, including a partnership with the Malaysian Tourism Board [8] - Yonyou's Malaysia General Manager focused on the role of digital tools in enhancing operational efficiency for outbound enterprises and the global opportunities they present [10] Group 3: Roundtable Discussion - A roundtable discussion featured prominent figures discussing how cultural exchange can empower China-Malaysia cooperation, emphasizing the importance of policy communication and cultural connectivity [13] Group 4: Future Initiatives - The forum marked the first entry of Phoenix TV's international brand "Phoenix Goes Global" into Malaysia, with plans to launch in Indonesia in December 2024, aiming to become a preferred platform for outbound enterprises [15]

香港联交所最新资料显示，12月9日，小摩减持白云山(00874)11.2万股，每股作价18.581港元，总金额 约为208.11万港元。减持后最新持股数目约为1969.23万股，最新持股比例为8.95%。 ...

智通财经APP讯，白云山(00874)发布公告，近日，广东省药品监督管理局发布了《广东省药品监督管理 局关于注销<药品生产许可证>的通告(2025年第102号)》，广州白云山医药集团股份有限公司(以下简 称"本公司")子公司广州白云山星珠药业有限公司(以下简称"星珠药业")《药品生产许可证》已注销，本 次注销的原因是星珠药业进行生产经营业务调整，在生产范围为中药饮片的《药品生产许可证》有效期 届满后不再申请重新发证。 星珠药业进行生产经营业务调整，将主要业务集中在中药前处理提取业务上，在生产范围为中药饮片的 《药品生产许可证》有效期届满后，不再申请重新发证，将该《药品生产许可证》注销。星珠药业2024 年中药饮片业务没有产生营业收入。 ...